ELAN - Elanco Animal Health Incorporated

NYSE - Nasdaq Real-time price. Currency in USD
30.59
-0.39 (-1.26%)
As of 12:03PM EST. Market open.
Stock chart is not supported by your current browser
Previous close30.98
Open31.07
Bid30.59 x 1200
Ask30.60 x 1100
Day's range30.53 - 31.21
52-week range25.25 - 35.46
Volume1,757,725
Avg. volume4,890,722
Market cap12.174B
Beta (5Y monthly)N/A
PE ratio (TTM)121.39
EPS (TTM)0.25
Earnings date18 Feb 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.43
  • Business Wire

    Elanco’s East Africa Growth Accelerator Delivers $8+ Million in Socio-Economic Value for Smallholder Farmers in East Africa, Progress Against Sustainable Development Goals

    Elanco Animal Health Inc. (NYSE: ELAN) today announced that its shared value East Africa Growth Accelerator (EAGA) initiative has delivered a Social Return on Investment (SROI) of almost 250% for dairy and poultry smallholder farmers, their families and other stakeholders in the region. For every US$1 invested by Elanco and its partners in the EAGA initiative during its initial phase from June 2017 to December 2018, $2.48 of socio-economic value has been created for society in East Africa.

  • Business Wire

    Elanco Signs Agreement with Vetoquinol to Divest Rights for Drontal® and Profender® Within the European Economic Area and the United Kingdom

    Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has signed an agreement to divest the European Economic Area and UK rights to the Drontal® and Profender® product families from Bayer AG’s (ETR: BAYN) animal health business, to Vetoquinol SA (EURONEXT: VETO), a French pharmaceutical company, for $140 million in an all-cash deal subject to customary post-closing adjustments. Drontal and Profender are both de-wormers for dogs and cats.

  • Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q4 Earnings Expected to Decline
    Zacks

    Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q4 Earnings Expected to Decline

    Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • New Strong Sell Stocks for February 11th
    Zacks

    New Strong Sell Stocks for February 11th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Business Wire

    Elanco Animal Health Announces Pricing and Upsize of Senior Secured Term Loan Facilities

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it successfully priced its first lien senior secured credit facilities consisting of (i) a term loan B facility in an aggregate principal amount of $4,275.0 million with a maturity of seven years and (ii) a revolving loan facility providing up to $750.0 million with a maturity of five years. The amount of the term loan B facility was upsized from the initial amount of $2,425.0 million due to market demand. The term loan B facility will be priced at par at LIBOR plus 175 basis points and the revolving loan facility is expected to bear interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on Elanco’s corporate family rating or corporate credit rating.

  • Business Wire

    Elanco Animal Health Announces Strategic Alliance With Purdue University and Purdue Research Foundation

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced a four-year agreement with Purdue University and Purdue Research Foundation with the goal to collaborate and train talent, as Elanco seeks solutions to solve some of the greatest challenges in animal health.

  • Business Wire

    Elanco Confirms Date and Conference Call for 2019 Fourth Quarter Financial Results

    Elanco Animal Health Incorporated (NYSE: ELAN) will announce its 2019 fourth quarter financial results on Wednesday, February 19, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.

  • Business Wire

    Elanco Animal Health Announces Upsizing and Pricing of Common Stock and Pricing of Tangible Equity Unit Offerings

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced that is has priced its previously announced concurrent public offerings of 22,694,732 shares of its common stock at $32.00 per share and 11,000,000 of its 5.00% tangible equity units, with a stated amount of $50 per unit. The common stock offering was upsized from the previously announced offering size of 19,159,866 shares of common stock. The common stock offering and tangible equity unit offering are separate public offerings made by means of separate prospectus supplements under Elanco’s effective shelf registration statement and are not contingent on each other or upon the consummation of the acquisition discussed below. Elanco’s common stock is listed on the New York Stock Exchange under the symbol "ELAN" and Elanco has applied to list the tangible equity units on the New York Stock Exchange under the symbol "ELAT." The offerings are expected to close on January 27, 2020, subject to customary closing conditions.

  • Business Wire

    Elanco Animal Health Announces Common Stock and Tangible Equity Unit Offerings Associated with Financing Acquisition of Bayer’s Animal Health Business

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced it intends to make concurrent public offerings of 19,159,866 shares of its common stock and 11,000,000 tangible equity units, with an aggregate stated amount of $550 million for the units. Each tangible equity unit has a stated amount of $50 and is composed of (i) a prepaid stock purchase contract and (ii) a senior amortizing note due February 1, 2023 each issued by Elanco. The common stock offering and tangible equity unit offering are separate public offerings made by means of separate prospectus supplements under Elanco’s effective shelf registration statement and are not contingent on each other or upon the consummation of the acquisition discussed below. Elanco’s common stock is listed on the New York Stock Exchange under the symbol "ELAN" and Elanco has applied to list the tangible equity units on the New York Stock Exchange under the symbol "ELAT."

  • Elanco (ELAN) Surges: Stock Moves 5.3% Higher
    Zacks

    Elanco (ELAN) Surges: Stock Moves 5.3% Higher

    Elanco (ELAN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • New Strong Sell Stocks for January 14th
    Zacks

    New Strong Sell Stocks for January 14th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Business Wire

    Elanco Signs Agreement with PetIQ to Divest Capstar®

    Elanco Animal Health Incorporated (NYSE: ELAN) announced today it signed an agreement to divest the U.S. rights to Capstar®, an oral tablet that kills fleas in dogs and cats, to PetIQ, Inc. (Nasdaq: PETQ), a leading pet medication and wellness company, for $95 million in an all-cash deal. The product had 2018 revenue of $28.5 million.

  • Business Wire

    Elanco Announces 2020 Financial Guidance

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced its initial financial guidance for 2020, including total revenue expectations in the range of $3.05 billion to $3.11 billion, and Core Revenue, which excludes strategic exits, in the range of $3.00 billion to $3.06 billion. Elanco also expects earnings per share (EPS) for 2020 to be in the range of $0.04 to $0.16 on a reported basis and $1.09 to $1.16 on an adjusted basis. These revenue and EPS expectations are for stand-alone Elanco only, including full year revenues for products that may be divested, and do not include any expected revenues from the Bayer animal health business or impact of transactions related to the acquisition, such as potential issuance of additional shares.

  • Business Wire

    Elanco Confirms Date for 2020 Financial Guidance Announcement

    Elanco Animal Health Incorporated (NYSE: ELAN) will announce its financial guidance for 2020 on Friday, January 10, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s financial guidance.

  • Business Wire

    Elanco Signs Agreement with Dechra to Divest Osurnia®

    Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has signed an agreement to divest Osurnia®, a treatment for otitis externa in dogs, to Dechra Pharmaceuticals PLC (LON: DPH) for $135 million in an all-cash deal.

  • Business Wire

    Elanco to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. ET (9:30 a.m. PT).

  • Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals
    Zacks

    Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals

    Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.

  • Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio
    Zacks

    Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio

    Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.

  • Investors Who Bought Elanco Animal Health (NYSE:ELAN) Shares A Year Ago Are Now Down 23%
    Simply Wall St.

    Investors Who Bought Elanco Animal Health (NYSE:ELAN) Shares A Year Ago Are Now Down 23%

    The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

  • Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More
    Zacks

    Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More

    Rise in senior population, shift of care to lower-cost settings and decline in unemployment are likely to have driven healthcare sector earnings.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more